Verde Servicos Internacionais S.A. Purchases Shares of 7,500 Eli Lilly and Company (NYSE:LLY)

Verde Servicos Internacionais S.A. bought a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 7,500 shares of the company's stock, valued at approximately $5,790,000. Eli Lilly and Company comprises about 2.5% of Verde Servicos Internacionais S.A.'s holdings, making the stock its 16th largest position.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Algert Global LLC boosted its position in shares of Eli Lilly and Company by 27.9% during the 2nd quarter. Algert Global LLC now owns 504 shares of the company's stock worth $456,000 after purchasing an additional 110 shares in the last quarter. Granite Bay Wealth Management LLC bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $323,000. RiverFront Investment Group LLC bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth $256,000. Strategic Investment Solutions Inc. IL acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $565,000. Finally, Clear Rock Advisors LLC bought a new stake in Eli Lilly and Company during the 2nd quarter valued at $229,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY traded up $19.51 during trading hours on Thursday, hitting $823.59. The stock had a trading volume of 2,641,752 shares, compared to its average volume of 3,922,555. Eli Lilly and Company has a 1 year low of $637.00 and a 1 year high of $972.53. The company's fifty day simple moving average is $780.80 and its 200 day simple moving average is $845.98. The stock has a market cap of $781.85 billion, a PE ratio of 89.04, a price-to-earnings-growth ratio of 1.59 and a beta of 0.41. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter in the prior year, the business earned $0.10 EPS. Eli Lilly and Company's revenue for the quarter was up 20.4% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company declared that its board has authorized a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company's payout ratio is currently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.13% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on LLY shares. Redburn Atlantic raised shares of Eli Lilly and Company to a "hold" rating in a research report on Monday, November 4th. Truist Financial lifted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a "buy" rating in a research report on Thursday, October 10th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an "outperform" rating and a $1,100.00 price target for the company. Wolfe Research began coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They set an "outperform" rating and a $1,000.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating for the company in a report on Monday, November 4th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $997.22.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.